NOXXON’s SDF-1 inhibitor NOX-A12 completes Phase I
Advertisement
NOXXON Pharma announced the completion of Phase I single and multiple dose clinical trials of its SDF-1 inhibitor NOX-A12. In phase I studies with healthy volunteers single doses of NOX-A12 up to 10.8 mg/kg and daily doses up to 2 mg/kg for five days were found to be safe and well tolerated and resulted in dose-dependent mobilization of white blood cells and CD34+ cells as predicted by preclinical studies.
Based on compelling pre-clinical data in hematological and solid tumors, NOXXON believes that NOX-A12 has the potential to be developed for treatment of multiple oncology indications. Initiation of the first Phase IIa trial of NOX-A12 in a hematological tumor indication is planned early in 2012, subject to regulatory and ethics committee approvals.